{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:28:14Z","timestamp":1792549694969,"version":"4.5.0"},"reference-count":64,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec id=\"ab-noi250045-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>With increased payer coverage and the advent of antiamyloid therapies, clinical use of amyloid positron emission tomography (PET) is likely to increase to help guide the diagnosis and treatment of patients with cognitive impairment. However, unlike most previous research studies, in clinical practice, scan acquisition is less standardized, interpretation typically relies purely on visual reads rather than scan quantification, and patients have more frequent comorbidities, all of which might compromise test accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250045-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare visual interpretation of amyloid-PET in real-world clinical settings to scan interpretation based on central quantification, in order to assess the accuracy of clinical reads.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250045-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cross-sectional quality improvement study used data from the Imaging Dementia\u2014Evidence for Amyloid Scanning study, collected between February 2016 and January 2018 and analyzed between December 2021 and April 2023. The setting included 294 imaging facilities in the US. Medicare beneficiaries 65 years or older with cognitive decline for whom Alzheimer disease was a diagnostic consideration were recruited by dementia specialists from their clinical practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250045-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Amyloid-PET with [18F]florbetapir, [18F]florbetaben, or [18F]flutemetamol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250045-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>PET scans were visually interpreted as positive or negative by local radiologists or nuclear medicine physicians following approved guidelines. Independently, scans were centrally processed and quantified using the standardized Centiloid (CL) scale. We applied an a priori autopsy-based threshold of 24.4 CL to quantitatively define scan positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250045-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 18\u202f293 participants included in the parent study, scan images were available for 10\u202f774 (59%), of which Centiloids were successfully calculated for 10\u202f361 (96%). Median (IQR) patient age was 75 (71-80) years; 5245 patients (51%) were female, 6500 (63%) had mild cognitive impairment, and 3861 (37%) had dementia). Participants self-reported the following races and ethnicities: 1 Alaska Native (0%), 23 American Indian (0.2%), 188 Asian (1.8%), 316 Black (3.1%), 449 Hispanic or Latino (4.3%), 8 Native Hawaiian or Other Pacific Islander (0.1%), and 9125 White (88.2%). A total of 6332 scans (61%) were visually read as positive, and 6121 (59%) were quantitatively positive. Agreement between visual reads and quantitative classification was 86.3% (95% CI, 85.7%-87.0%; Cohen \u03ba\u2009=\u20090.72; 95% CI, 0.70-0.73). A total of 5519 (53%) scans were positive visually and quantitatively (V+\/Q+), 3416 (33%) were negative by both (V\u2212\/Q\u2212), 813 (8%) were V+\/Q\u2212, and 602 (6%) were V\u2212\/Q+. Female sex (female: 4581\/5241 [87.4%]; male: 4354\/5109 [85.2%];\n                      <jats:italic>P<\/jats:italic>\n                      =.001), White race (White race: 7900\/9125 [86.6%]; non-White race: 1035\/1225 [84.5%];\n                      <jats:italic>P<\/jats:italic>\n                      =.046), and use of [18F]flutemetamol and [18F]florbetaben ([18F]flutemetamol: 559\/628 [89.0%]; [18F]florbetaben: 2664\/3032 [87.9%]; [18F]florbetapir: 5712\/6690 [85.4%];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;amp;lt;.001), compared with [18F]florbetapir, were associated with higher visual-quantitative concordance. Scans within a 10- to 40-CL borderline positivity zone were more likely to be discordant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250045-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cross-sectional study found high concordance between local visual reads and central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET visual reads in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.2218","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:00:27Z","timestamp":1753714827000},"page":"952","source":"Crossref","is-referenced-by-count":40,"title":["Concordance Between Amyloid-PET Quantification and Real-World Visual Reads"],"prefix":"10.1001","volume":"82","author":[{"given":"Ehud","family":"Zeltzer","sequence":"first","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"},{"name":"Indiana Regional Medical Center, Indiana, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Schonhaut","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi S.","family":"Mundada","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"},{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganna","family":"Blazhenets","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Soleimani-Meigooni","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Cho","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"},{"name":"Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalini G.","family":"Ranasinghe","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Windon","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Yadollahikhales","sequence":"additional","affiliation":[{"name":"Jona Goldrich Center for Alzheimer\u2019s and Memory disorders, Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Apgar","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation, American College of Radiology, Reston, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Gatsonis","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island"},{"name":"Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Carrillo","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Association, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Romanoff","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Hillner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Virginia Commonwealth University, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Koeppe","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"March","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation, American College of Radiology, Reston, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smith","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Whitmer","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Department of Neurology, Alzheimer\u2019s Disease Research Center, University of California Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"},{"name":"Eli Lilly and Co, Sesto Fiorentino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"},{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco"},{"name":"Associate Editor, JAMA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Center, Memory and Aging Center, Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"noi250045r1","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review.","volume":"63","author":"Chapleau","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"noi250045r2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jalz.2018.02.022","article-title":"Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET.","volume":"14","author":"Altomare","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"13","key":"noi250045r3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia.","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"noi250045r4","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jalz.2019.07.003","article-title":"Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: the ABIDE project.","volume":"15","author":"de Wilde","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi250045r5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mhw.33505","article-title":"FDA approves new treatment for Alzheimer disease.","volume":"33","author":"Canady","year":"2023","journal-title":"Ment Health Wkly"},{"issue":"1","key":"noi250045r8","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"8","key":"noi250045r9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/alz.12293","article-title":"Generalizability of findings from a clinical sample to a community-based sample: a comparison of ADNI and ARIC.","volume":"17","author":"Gianattasio","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi250045r10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jalz.2010.03.007","article-title":"The Alzheimer\u2019s Disease Neuroimaging Initiative: progress report and future plans.","volume":"6","author":"Weiner","year":"2010","journal-title":"Alzheimers Dement"},{"issue":"9","key":"noi250045r11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/ene.13374","article-title":"Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer disease.","volume":"24","author":"Moonga","year":"2017","journal-title":"Eur J Neurol"},{"issue":"8","key":"noi250045r13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u00df plaques: a prospective cohort study.","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"issue":"8","key":"noi250045r14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study.","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi250045r15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol"},{"issue":"12","key":"noi250045r19","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale.","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"12","key":"noi250045r20","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","article-title":"18F-Florbetaben PET \u00df-amyloid binding expressed in Centiloids.","volume":"44","author":"Rowe","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"noi250045r21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","article-title":"Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods.","volume":"8","author":"Battle","year":"2018","journal-title":"EJNMMI Res"},{"issue":"8","key":"noi250045r22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","article-title":"Standardized expression of 18F-NAV4694 and 11C-PiB \u00df-amyloid PET results with the Centiloid scale.","volume":"57","author":"Rowe","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"noi250045r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid project: standardizing quantitative amyloid plaque estimation by PET.","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"12","key":"noi250045r24","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"noi250045r25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer disease neuropathology.","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi250045r26","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14528","article-title":"Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer disease.","volume":"21","author":"Leuzy","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi250045r27","doi-asserted-by":"publisher","first-page":"e-1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association.","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"7","key":"noi250045r28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2967\/jnumed.113.127068","article-title":"Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education.","volume":"54","author":"Johnson","year":"2013","journal-title":"J Nucl Med"},{"issue":"6","key":"noi250045r29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1062860615605176","article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.","volume":"30","author":"Ogrinc","year":"2015","journal-title":"Am J Med Qual"},{"issue":"8","key":"noi250045r30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","article-title":"SNMMI procedure standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0.","volume":"57","author":"Minoshima","year":"2016","journal-title":"J Nucl Med"},{"key":"noi250045r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data.","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage"},{"issue":"1","key":"noi250045r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100008","article-title":"Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer\u2019s Association Research Roundtable.","volume":"12","author":"Farrar","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"noi250045r34","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer disease: Alzheimer\u2019s Association Workgroup.","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi250045r35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic.","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"issue":"3","key":"noi250045r37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations.","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"noi250045r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations.","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"noi250045r39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.14283\/jpad.2024.37","article-title":"Anti-amyloid therapies for Alzheimer disease: an Alzheimer Europe position paper and call to action.","volume":"11","author":"Bradshaw","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"noi250045r40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","article-title":"Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.","volume":"13","author":"Royse","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"noi250045r41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.14283\/jpad.2021.4","article-title":"Amyloid and APOE status of screened subjects in the elenbecestat missionad phase 3 program.","volume":"8","author":"Roberts","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"noi250045r42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"noi250045r43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"20","key":"noi250045r44","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer disease.","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"noi250045r45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3233\/JAD-142229","article-title":"Visual vs semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer\u2019s Disease Consortium (EADC) project.","volume":"44","author":"Morbelli","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"noi250045r46","first-page":"1109","article-title":"Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.","volume":"46","author":"Koch","year":"2005","journal-title":"J Nucl Med"},{"issue":"11","key":"noi250045r47","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00702-016-1586-6","article-title":"Visual vs automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.","volume":"123","author":"M\u00e4kinen","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"noi250045r48","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.14336\/AD.2019.1103","article-title":"Six visual rating scales as a biomarker for monitoring atrophied brain volume in parkinson\u2019s disease.","volume":"11","author":"Lin","year":"2020","journal-title":"Aging Dis"},{"issue":"2","key":"noi250045r49","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3397","article-title":"Regional MRI volumetry using NeuroQuant vs visual rating scales in patients with cognitive impairment and dementia.","volume":"14","author":"Persson","year":"2024","journal-title":"Brain Behav"},{"issue":"11","key":"noi250045r50","doi-asserted-by":"publisher","first-page":"7789","DOI":"10.1007\/s00330-021-08503-7","article-title":"Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer disease.","volume":"32","author":"Ingala","year":"2022","journal-title":"Eur Radiol"},{"issue":"11","key":"noi250045r51","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","article-title":"Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.","volume":"50","author":"Jovalekic","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"noi250045r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101846","article-title":"Semi-quantification and grading of amyloid PET: a project of the European Alzheimer\u2019s Disease Consortium (EADC).","volume":"23","author":"Chincarini","year":"2019","journal-title":"Neuroimage Clin"},{"issue":"7","key":"noi250045r53","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","article-title":"A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images.","volume":"48","author":"Bucci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"noi250045r54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2967\/jnumed.124.268119","article-title":"Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study.","volume":"66","author":"Collij","year":"2025","journal-title":"J Nucl Med"},{"issue":"4","key":"noi250045r55","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 study: design of a prevention trial for Alzheimer disease.","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"12","key":"noi250045r56","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer disease.","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"noi250045r57","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"noi250045r58","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"noi250045r59","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer disease.","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"noi250045r60","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease.","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"noi250045r61","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/RLU.0000000000001693","article-title":"Augmenting amyloid PET interpretations with quantitative information improves consistency of early amyloid detection.","volume":"42","author":"Harn","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"5","key":"noi250045r62","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00259-016-3601-4","article-title":"Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging.","volume":"44","author":"Pontecorvo","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"noi250045r63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00401-012-0943-2","article-title":"Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.","volume":"123","author":"Ikonomovic","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"1","key":"noi250045r64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","article-title":"Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer disease.","volume":"12","author":"Amadoru","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"noi250045r36","doi-asserted-by":"crossref","DOI":"10.1002\/0471445428","volume-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"2003"},{"key":"noi250045r6","unstructured":"US Food and Drug Administration. FDA converts novel Alzheimer disease treatment to traditional approval. Accessed December 5, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"},{"key":"noi250045r7","unstructured":"US Food and Drug Administration. FDA approves treatment for adults with Alzheimer disease. Accessed December 5, 2024. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease"},{"key":"noi250045r12","unstructured":"Jacques? L, Jensen? TS, Rollins? J, . Beta amyloid positron emission tomography in dementia and neurodegenerative disease. Accessed August 8, 2022. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&NCAId=265"},{"key":"noi250045r16","unstructured":"Neuraceq. Press release Piramal Life Sciences. Accessed Month Day, Year. https:\/\/www.piramal.com\/wp-content\/uploads\/2020\/04\/USFBB041400-aan-press-release-1-1.pdf"},{"key":"noi250045r17","unstructured":"Amyvid. Package insert Eli Lilly and Co.  https:\/\/pi.lilly.com\/us\/amyvid-uspi.pdf"},{"key":"noi250045r18","unstructured":"Vizamyl. Package insert GE Healthcare. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/203137s005lbl.pdf"},{"key":"noi250045r32","unstructured":"GitHub. Robust PET-only processing, aka rPOP. Accessed June 24, 2025. https:\/\/github.com\/LeoIacca\/rPOP"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2836764\/jamaneurology_zeltzer_2025_oi_250045_1756927751.69884.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:01:17Z","timestamp":1757343677000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2836764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.2218","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.31.24316518","asserted-by":"object"}]},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}